P-glycoprotein—a clinical target in drug-refractory epilepsy?

Robert W. Robey[1,4]

Alberto Lazarowski[2,3]

Susan E. Bates[1]

[1]Medical Oncology Branch, Center for Cancer Research, National Cancer Institute,
National Institutes of Health, Bethesda, MD 20892; [2]Clinical Biochemistry Department,
School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina; [3]E. de
Robertis Neuroscience Research Institute, University of Buenos Aires, Argentina

[4]Corresponding author:

9000 Rockville Pike

Bldg 10 Rm 12C217

Bethesda, MD 20892

Ph: 301-496-0796

robeyr@mail.nih.gov

Running Title: P-glycoprotein in refractory epilepsy

1

ABSTRACT

ATP-binding cassette transporters such as P-glycoprotein (Pgp), multidrug resistance-associated protein and breast cancer resistance protein are known to transport a wide range of substrates and are highly expressed in the capillary endothelial cells that form part of the blood-brain barrier. Interestingly, P-glycoprotein has been shown to be upregulated in animal models of refractory epilepsy and adding a Pgp inhibitor to treatment regimens has been shown to reverse the drug-resistant phenotype. Limited data have suggested a role for Pgp in epilepsy in humans as well. However, few epilepsy drugs have been shown to be transported by Pgp, leading to controversy over whether or not Pgp actually plays a role in drug-resistant epilepsy. In this issue of *Molecular Pharmacology*, Bauer and colleagues demonstrate that glutamate can cause localized upregulation of Pgp via COX-2, and that this phenomenon can be prevented with COX-2 inhibitors. Localized rather than global upregulation of Pgp may explain some of the difficulty investigators have had in proving a role for Pgp in epilepsy. The results add new support for future clinical trials targeting Pgp expression in drug-refractory epilepsy.

Overexpression of ATP-binding cassette (ABC) transporters such as P-glycoprotein (ABCB1, Pgp), multidrug-resistance associated protein (ABCC1, MRP) and breast cancer resistance protein (ABCG2, BCRP) in cancer cells confers a drug-resistant phenotype by transporting a diverse range compounds out of the cell against a concentration gradient (Gottesman et al., 2002). It is the expression of these transporters in the blood-brain barrier (BBB) and their promiscuous nature that has made them attractive targets of study as the potential cause of drug-resistant epilepsy.

In the fields of cancer and epilepsy, we seem to be working on the same puzzle, seeking to establish a case for the role of ABC transporters such as Pgp in drug resistance. However, different pieces have fallen into place in each field. In oncology, we know that many of the drugs we use to treat cancer are Pgp substrates and we can identify overexpression of Pgp in certain cancers; however, we have not been able to convincingly demonstrate significant clinical benefit when we combine Pgp substrate drugs with an inhibitor. In neurology, it seems established that Pgp is upregulated in refractory epilepsy in animals and humans; and, while adding a Pgp inhibitor reverses drug-resistant epilepsy in animal models and (anecdotally) in patients, few epilepsy drugs have been shown to be transported by Pgp.

Fueling the argument that ABC transporters play a role in drug-resistant epilepsy is the nature of the BBB itself. The brain endothelial cells that form the BBB are characterized by expression of several ABC transporters such as Pgp, ABCG2, and

multidrug resistance-associated proteins (MRPs) such as MRP1, 2, 4 and 5 (Deeken and Loscher, 2007). Pgp and ABCG2 have been found to be highly expressed and colocalized in brain microvasculature (Sisodiya et al., 2006). Mice that are deficient in Abcb1a or Abcg2 have increased brain penetration of substrate compounds such as vinblastine (Cisternino et al., 2001) or imatinib (Breedveld et al., 2005), respectively. Thus, the ability of ABC transporters to limit brain penetration of cancer drugs may extend to anti-epileptic drugs (AEDs). Such a possibility has led to several studies examining expression of Pgp in models of sensitive and resistant epilepsy as well as in patients.

Lazarowski and colleagues noted an increase in Pgp expression predominantly in brain capillary endothelium, astrocytes and neurons in rats experiencing repeated seizures for 4 or 7 days, respectively (Lazarowski et al., 2004b), suggesting that repeated seizures can trigger upregulation of Pgp. Volk and Loscher extended these observations by electrically inducing seizures in rats, treating the rats with phenobarbital to determine responders and non-responders to the drug and subsequently examining Pgp expression in the brains of the two groups (Volk and Loscher, 2005). They found up to a 4-fold increase of the Pgp-labelled area in capillary endothelial cells at the piriform cortex of non-responders compared to responders (Volk and Loscher, 2005). These results were mirrored in studies of refractory epilepsy in humans. Increased expression of Pgp, as well as MRP, has been associated with refractory epilepsy in tuberous sclerosis (Lazarowski et al., 2004a). Increased levels of Pgp were found in astrocytes and blood vessel endothelium in hippocampal samples obtained from patients with refractory mesial

4

temporal lobe epilepsy compared to control samples (Aronica et al., 2004). Ak et al. found increased expression of Pgp and MRP in neurons, astrocytes and endothelial cells at the epileptogenic zone in samples taken from patients with focal cortical dysplasia (Ak et al., 2007). Clearly, increased levels of Pgp in the brain are associated with seizure and are found in refractory epilepsy.

Animal models of drug resistant epilepsy seem to firmly establish a role for Pgp as a target for increasing clinical response to current epilepsy treatments. Overexpression of Pgp has been demonstrated, and the administration of a Pgp inhibitor such as tariquidar has been shown to overcome drug resistance in animal models of drug-resistant epilepsy (Brandt et al., 2006; van Vliet et al., 2006; Volk and Loscher, 2005). More recently, it was documented that adjuvant treatment with nimodipine, a calcium channel blocker that also inhibits Pgp activity, was able to restore the normal hippocampal pharmacokinetics of phenytoin (PTH) with total seizure control, avoiding epilepticus status-associated death in a PTH-refractory epilepsy model (Hocht et al., 2007; Lazarowski et al., 2007b). In humans, there are anecdotal accounts of verapamil reversing drug-resistant epilepsy (Iannetti et al., 2005; Summers et al., 2004). Two reports involving only single cases have appeared; overexpression of Pgp was not confirmed and inhibition of Pgp was not validated. As an aside, it should be noted that there remains the possibility that the success of Pgp inhibitors in controlling seizures in animal models, and possibly in humans, has another mechanism than inhibition of AED transport mediated by Pgp.

One major point of controversy centers around the identification of AEDs that are substrates for efflux by drug transporters, particularly by human Pgp. While early studies seemed to suggest some AEDs were transported by Pgp (Schinkel et al., 1996), recent studies by Baltes et al. (Baltes et al., 2007) and Crowe et al. (Crowe and Teoh, 2006) imply that human and murine Pgp have different substrate specificities and that relatively few AEDs are transported by Pgp. However, the sensitivity of their model system was not determined. To validate the model system used, MDCKII canine kidney or LLC-PK1 pig kidney cells transfected with MDR1 (Baltes et al.) or Caco-2 cells (Crowe et al.), well-known compounds that are readily transported by Pgp were used. What was not included was a compound that is a known substrate of Pgp, but that has poor transport efficiency, thus enabling one to gauge the sensitivity of the assay. It may be that AEDs are Pgp substrates, but are not so well transported that they can be detected by the model systems used. Additionally, it is not clear whether Pgp levels in the model systems accurately represent Pgp levels in brain capillaries of patients with drug-resistant epilepsy.

Since significant transport of AEDs by human Pgp has not been conclusively demonstrated, investigators have recently asked whether other transporters including ABCG2 are involved. ABCG2 has been localized to the brain microvessel endothelium in rodents (Hori et al., 2004; Lee et al., 2007) and humans (Cooray et al., 2002) and has been found to co-localize with Pgp (Sisodiya et al., 2006), suggesting it plays a critical role in the BBB. Recent studies do not seem to suggest that ABCG2 significantly transports many drugs used to treat epilepsy (Cerveny et al., 2006); however, definitive studies are needed.

In the current study by Bauer and colleagues, we are provided with additional

evidence supporting a role for Pgp in drug-resistant epilepsy. The authors demonstrate

that Pgp overexpression can be induced locally by microinjection of glutamate, which

increases levels of COX-2 (Bauer et al., 2007). Glutamate-injected rats were found to

have significantly increased levels of Pgp in the right hilus, located ventral to the

injection site, compared to vehicle-injected controls (Bauer et al., 2007). Interestingly,

Bauer at al. also demonstrated that intracerebral microinjections of glutamate at

nanomolar levels, were sufficient to locally increase P-glycoprotein expression without

seizure activity (Bauer et al., 2007). The increased expression of Pgp was found occur in

the endothelium of existing, and not newly-formed, capillaries. Pgp expression in more

distal regions of the brain was not significantly affected. These particular data suggest

that molecular factors inducing Pgp overexpression in the BBB, even in the absence of

seizures, could precondition the refractory phenotype for some epileptic syndromes.

It should be noted that the focus of this very important finding was limited to

BBB-vascular endothelial cells. In accordance with the recently defined "neurovascular

unit" for stroke by del Zoppo (del Zoppo, 2006), we believe that the critical role for mdr-

1 gene induction should be extended to other brain cells, such as astrocytes and neurons,

not only in hypoxic conditions (Lazarowski et al., 2007a), but also in epilepsy.

Several studies in cancer systems have posited a link between COX-2 expression

and Pgp expression. Fantappie et al found that COX-2 and iNOS expression was

7

upregulated in a doxorubicin-selected, Pgp overexpressing cell line (Fantappie et al., 2002). Simlarly, Surowiak et al. found that invasive breast cancer tumor samples that were COX-2 positive also had higher expression of Pgp and that increased COX-2 and Pgp were negative prognostic factors (Surowiak et al., 2005). When Patel and colleagues transferred rat Cox-2 into rat mesangial cells via adenovirus, they noted an increase in Pgp expression and function that correlated with the increase in Cox-2 mRNA expression (Patel et al., 2002). The increase in Cox-2 and Pgp could be prevented by incubating infected cells with the Cox-2 inhibitor NS398, again reinforcing the link between COX-2 and Pgp (Patel et al., 2002). The results obtained by Bauer et al., continue this line of evidence, as Pgp upregulation in the epileptic rat brain capillaries could be prevented by the COX-2 inhibitor celecoxib.

Thus, the findings of Bauer and colleagues suggest that upregulation of Pgp may be a local, but not global, effect and thus may not be able to be detected in studies that measure whole brain uptake of drugs. Indeed, there is conflicting evidence with regard to uptake of Pgp substrates in the drug-resistant brain in humans. One study found no differential transport of verapamil in epileptogenic versus nonepiloeptogenic tissue in patients diagnosed with refractory epilepsy (Langer et al., 2007), while another found that increased levels of Pgp were associated with decreased levels of a metabolite of oxcarbazepine (Marchi et al., 2005). In the study by Langer and colleagues, they point out that the data do not exclude the possibility that enhanced Pgp-mediated efflux in some regions of the brain is responsible for resistance to AEDs in some patients (Langer et al., 2007).

In oncology, there was a rush to clinical trial, before the best inhibitors were developed and before it was clear in which cancers Pgp overexpression was important. This resulted in many negative trials and the failure to confirm a role for Pgp in multidrug resistance in cancer. In epilepsy, investigators have been cautious, awaiting clear and convincing evidence to confirm a role for Pgp (Sisodiya and Bates, 2006). Perhaps as a result of this careful approach, convincing animal data for a role in epilepsy have been gathered, and are much stronger than any evidence attained for Pgp. The remaining question seems to be determining which substrates are involved. The paper by Bauer et al. suggests a new strategy–COX-2 inhibitors for the prevention of drug resistance in epilepsy. Bauer notes there is concern regarding the side-effects of COX-2 inhibitors which resulted in the removal of FDA approval for celecoxib (Sarkar et al., 2007), although the risk may be offset by the adverse impact of chronic, refractory epilepsy. P-glycoprotein inhibitors have already been used in patients with chemotherapy (Kuppens et al., 2007; Peck et al., 2001; Pusztai et al., 2005) and some, such as tariquidar (Robey et al., 2004) and biricodar (Minderman et al., 2004), inhibit multiple transporters. Chronic use of these compounds has never been attempted as most cancer treatment schedules are episodic and safety would be a concern. Despite the overall good health of Pgp-deficient mice, the increased toxicity with ivermectin suggests that there might be challenges in the event of xenobiotic exposure. These arguments aside, it may simply be time to translate the most promising animal studies to the clinic. A well-designed clinical trial may allow a leap forward for science of epilepsy, and for patients suffering from the disease.

REFERENCES

Ak H, Ay B, Tanriverdi T, Sanus GZ, Is M, Sar M, Oz B, Ozkara C, Ozyurt E and Uzan M (2007) Expression and cellular distribution of multidrug resistance-related proteins in patients with focal cortical dysplasia. *Seizure* **16**(6):493-503.

Aronica E, Ozbas-Gerceker F, Redeker S, Ramkema M, Spliet WG, van Rijen PC, Leenstra S, Gorter JA and Troost D (2004) Expression and cellular distribution of high- and low-affinity neurotrophin receptors in malformations of cortical development. *Acta Neuropathol* **108**(5):422-434.

Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V and Loscher W (2007) Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. *Neuropharmacology* **52**(2):333-346.

Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS and Potschka H (2007) Seizure-Induced Upregulation of P-glycoprotein at the Blood-Brain Barrier through Glutamate and COX-2 Signaling. *Mol Pharmacol*.

Brandt C, Bethmann K, Gastens AM and Loscher W (2006) The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy. *Neurobiol Dis* **24**(1):202-211.

Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH and Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. *Cancer Res* **65**(7):2577-2582.

Cerveny L, Pavek P, Malakova J, Staud F and Fendrich Z (2006) Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents. *Epilepsia* **47**(3):461-468.

Cisternino S, Rousselle C, Dagenais C and Scherrmann JM (2001) Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice. *Pharm Res* **18**(2):183-190.

Cooray HC, Blackmore CG, Maskell L and Barrand MA (2002) Localisation of breast cancer resistance protein in microvessel endothelium of human brain. *Neuroreport* **13**(16):2059-2063.

Crowe A and Teoh YK (2006) Limited P-glycoprotein mediated efflux for anti-epileptic drugs. *J Drug Target* **14**(5):291-300.

Deeken JF and Loscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. *Clin Cancer Res* **13**(6):1663-1674.

del Zoppo GJ (2006) Stroke and neurovascular protection. *N Engl J Med* **354**(6):553-555.

Fantappie O, Masini E, Sardi I, Raimondi L, Bani D, Solazzo M, Vannacci A and Mazzanti R (2002) The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. *Hepatology* **35**(4):843-852.

Gottesman MM, Fojo T and Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. *Nature Rev Cancer* **2**(1):48-58.

Hocht C, Lazarowski A, Gonzalez NN, Auzmendi J, Opezzo JA, Bramuglia GF, Taira CA and Girardi E (2007) Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. *Neurosci Lett* **413**(2):168-172.

Hori S, Ohtsuki S, Tachikawa M, Kimura N, Kondo T, Watanabe M, Nakashima E and Terasaki T (2004) Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). *J Neurochem* **90**(3):526-536.

Iannetti P, Spalice A and Parisi P (2005) Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. *Epilepsia* **46**(6):967-969.

Kuppens IE, Witteveen EO, Jewell RC, Radema SA, Paul EM, Mangum SG, Beijnen JH, Voest EE and Schellens JH (2007) A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. *Clin Cancer Res* **13**(11):3276-3285.

Langer O, Bauer M, Hammers A, Karch R, Pataraia E, Koepp MJ, Abrahim A, Luurtsema G, Brunner M, Sunder-Plassmann R, Zimprich F, Joukhadar C, Gentzsch S, Dudczak R, Kletter K, Muller M and Baumgartner C (2007) Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. *Epilepsia* **48**(9):1774-1784.

Lazarowski A, Caltana L, Merelli A, Rubio MD, Ramos AJ and Brusco A (2007a) Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection? *J Neurol Sci* **258**(1-2):84-92.

Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S and D'Giano C (2007b) ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. *Epilepsia* **48 Suppl 5**:140-149.

Lazarowski A, Lubieniecki F, Camarero S, Pomata H, Bartuluchi M, Sevlever G and Taratuto AL (2004a) Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy. *Pediatr Neurol* **30**(2):102-106.

Lazarowski A, Ramos AJ, Garcia-Rivello H, Brusco A and Girardi E (2004b) Neuronal and glial expression of the multidrug resistance gene product in an experimental epilepsy model. *Cell Mol Neurobiol* **24**(1):77-85.

Lee G, Babakhanian K, Ramaswamy M, Prat A, Wosik K and Bendayan R (2007) Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems. *Pharm Res* **24**(7):1262-1274.

Marchi N, Guiso G, Rizzi M, Pirker S, Novak K, Czech T, Baumgartner C, Janigro D, Caccia S and Vezzani A (2005) A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. *Epilepsia* **46**(10):1613-1619.

Minderman H, O'Loughlin KL, Pendyala L and Baer MR (2004) VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. *Clin Cancer Res* **10**(5):1826-1834.

Patel VA, Dunn MJ and Sorokin A (2002) Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. *J Biol Chem* **277**(41):38915-38920.

Peck RA, Hewett J, Harding MW, Wang YM, Chaturvedi PR, Bhatnagar A, Ziessman H, Atkins F and Hawkins MJ (2001) Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. *J Clin Oncol* **19**(12):3130-3141.

Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G and Hortobagyi GN (2005) Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. *Cancer* **104**(4):682-691.

Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P and Bates SE (2004) Pheophorbide a is a specific probe for ABCG2 function and inhibition. *Cancer Res* **64**(4):1242-1246.

Sarkar FH, Adsule S, Li Y and Padhye S (2007) Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. *Mini Rev Med Chem* **7**(6):599-608.

Schinkel AH, Wagenaar E, Mol CA and van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. *J Clin Invest* **97**(11):2517-2524.

Sisodiya SM and Bates SE (2006) Treatment of drug resistance in epilepsy: one step at a time. *Lancet Neurol* **5**(5):380-381.

Sisodiya SM, Martinian L, Scheffer GL, van der Valk P, Scheper RJ, Harding BN and Thom M (2006) Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies. *Neuropathol Appl Neurobiol* **32**(1):51-63.

Summers MA, Moore JL and McAuley JW (2004) Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. *Ann Pharmacother* **38**(10):1631-1634.

Surowiak P, Materna V, Matkowski R, Szczuraszek K, Kornafel J, Wojnar A, Pudelko M, Dietel M, Denkert C, Zabel M and Lage H (2005) Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. *Breast Cancer Res* **7**(5):R862-870.

van Vliet EA, van Schaik R, Edelbroek PM, Redeker S, Aronica E, Wadman WJ, Marchi N, Vezzani A and Gorter JA (2006) Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. *Epilepsia* **47**(4):672-680.

Volk HA and Loscher W (2005) Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures. *Brain* **128**(Pt 6):1358-1368.

13